U.S. — Onswik is indicated as an adjunct to diet and exercise for adults with type 2 diabetes. The drug delivers steady basal insulin levels over 7 days.

"Onswik is designed to reduce injections by over 300 per year versus once-daily basal insulin," Eli Lilly said. "Insulin remains an important treatment option for many people with type 2 diabetes who do not achieve glycemic goals with other therapies."

The approval was based on data from the QWINT phase III clinical trials, which enrolled over 3,400 participants across four global studies. Julio Rosenstock, MD, of Velocity Clinical Research at Medical City in Dallas, was the lead investigator for the pivotal trials. "Efsitora is a new and further step in that direction to make life much easier for people with type 2 diabetes who need insulin," Rosenstock said.

The QWINT-2 trial demonstrated safety and efficacy among patients using and not using GLP-1 receptor agonists. In the QWINT-3 trial, which evaluated patients switching from daily basal insulin, efsitora achieved non-inferior HbA1c reductions at 26 weeks compared with insulin degludec U-100.

The QWINT-4 trial enrolled patients on more complex regimens involving basal insulin and at least two injections per day of mealtime insulin. In the QWINT-4 trial, efsitora showed non-inferior HbA1c reductions compared with once-daily insulin glargine U-100 at week 26.

In the QWINT trials, efsitora and glargine were both administered subcutaneously along with insulin lispro. "In these clinical trials, Onswik demonstrated an overall safety profile similar to the daily basal insulins studied," he said.

The most common adverse reactions to Onswik include hypoglycemia, hypersensitivity reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain. The Onswik label warns against use during active hypoglycemic episodes.

Prescribing information for Onswik cautions against medication errors, hypokalemia, and potential fluid retention or heart failure when co-administered with PPAR-gamma agonists, such as thiazolidinediones. Onswik is not approved for pediatric patients or individuals with type 1 diabetes due to a higher risk of severe hypoglycemia.

Eli Lilly plans to launch the Onswik KwikPen in the U.S. in the coming months. The Onswik KwikPen will be available in two concentration formats: 500 units/mL (1,500 total units per pen) and 1,000 units/mL (3,000 total units per pen).

Why It Matters

The approval introduces a second weekly basal insulin option for adults with type 2 diabetes who require insulin therapy but have not met glycemic goals with other treatments. By reducing the frequency of injections from daily to weekly, the regimen aims to lower the annual injection burden by more than 300 doses compared to standard daily basal insulin protocols.

Global regulatory momentum preceded the U.S. decision, with approvals already secured from the European Medicines Agency in June 2026, as well as authorities in Japan and Mexico. The clinical foundation for the drug involved thousands of participants across multiple countries, establishing non-inferiority against existing daily insulin standards in various patient populations, including those naive to insulin and those switching from complex regimens.

What's New

The QWINT clinical trials, which evaluated Onswik, included participants from 12 countries, including the U.S., Argentina, Hungary, Japan, and Spain. Corporate developments also emerged, as Eli Lilly signed a strategic licensing pact with InnoCare Pharma involving up to $100 million in near-term and upfront payments and approximately $3.25 billion in future commercial and development milestone payments. Primary source: ema.europa.eu

Records showed Onswik has previously received regulatory approvals in Europe, Japan, and Mexico. Under the new agreement, InnoCare Pharma will utilize its proprietary drug discovery platform to identify and progress compounds directed against up to five specific targets.